LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Add Yahoo as a preferred source to see more of our stories on Google. Dexcom received FDA clearance for its first over-the-counter continuous glucose monitor, called Stelo. The device is intended for ...
Add Yahoo as a preferred source to see more of our stories on Google. The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. Dexcom warned patients ...
Zacks Investment Research on MSN
DXCM secures Health Canada authorization for Dexcom G7 15 day CGM
DexCom DXCM recently announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System has received ...
Users can go to dexcom.com/theft-check for information on how to determine if sensors are from the affected lots and what action to take. Users also can call Dexcom Customer Support in the United ...
IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Blood glucose sensor and transmitter ...
Dexcom G7 15 Day is the longest‑lasting and most accurate 1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days 5. BURNABY, British ...
DexCom, Inc. DXCM reported third-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which beat the Zacks Consensus Estimate of 43 cents by 4.7%. The company had reported earnings of 50 cents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results